A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC) Meeting Abstract

  

Authors:	O'Reilly, E. M.; Abou-Alfa, G. K.; Letourneau, R.; Harker, W. G.; Modiano, M.; Hurwitz, H.; Tchekmedyian, N. S.; Ackerman, J.; De Jager, R. L.; Eckhardt, S. G.
Abstract Title:	A randomized phase III trial of DX-8951f (Exatecan Mesylate; DX) and Gemcitabine (GEM) vs. Gemcitabine alone in advanced pancreatic cancer (APC)
Meeting Title:	40th Annual Meeting of the American Society of Clinical Oncology (ASCO)
Journal Title:	Journal of Clinical Oncology
Volume:	22
Issue:	14 Suppl.
Meeting Dates:	2004 Jun 5-8
Meeting Location:	New Orleans, LA
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2004-07-15
Start Page:	315S
Language:	English
ACCESSION:	WOS:000223512401245
PROVIDER:	wos
DOI:	10.1200/jco.2004.22.90140.4006
Notes:	Meeting Abstract: 4006 -- 40th Annual Meeting of the American-Society-of-Clinical-Oncology -- JUN 05-08, 2004 -- New Orleans, LA -- S -- Source: Wos

https://synapse.mskcc.org/synapse/works/has_related_data_chk/57617